Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds

Lipids in Health and Disease

Hossam M. Omar³  Mohamed H. Mahmoud⁴  Gamal Badr³  Tarek H. El-Metwally¹  Sary Kh. Abd Elghaffar²  Sohair M. M. Ragab³ 

[1]Department of Medical Biochemistry, Faculty of Medicine, Assiut University, Assiut, Egypt

[2]Department of Pathology, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt

[3]Department of Zoology, Faculty of Science, Assiut University, Assiut 71516, Egypt

[4]Food Science and Nutrition Department, National Research Center, Dokki, Cairo, Egypt

关键词: Quercetin;    O-coumaric acid;    Dyslipidemia;    Non-alcoholic fatty liver disease;    Peroxisome proliferator-activated receptor γ;    High-fat high-sucrose diet;    Berberine;   

Others  :  1222147
DOI  :  10.1186/s12944-015-0087-1

 received in 2015-04-14, accepted in 2015-07-25,  发布年份 2015

【 摘 要 】

Background

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease with a complex pathophysiology. The clinical features of NAFLD include obesity, insulin resistance (IR) and dyslipidemia. Consumption of a diet high in saturated fats and sucrose is an important factor in the increasing occurrence of these metabolic disorders, primarily NAFLD and IR. We sought to assess the role of a high-fat, high-sucrose (HFS) diet in the promotion of NAFLD and to evaluate the effects of quercetin (Q), berberine (BB) and o-coumaric acid (CA) on modulation of these disorders.

Methods

Fifty male rats were divided into 2 main groups as follows: group 1 comprised 10 rats fed a standard diet (SD), and group 2 comprised 40 rats fed an HFS diet for 6 weeks and then subdivided equally into 4 groups; one of these groups served as the HFS diet and each of the other three groups received daily supplementation with either Q, CA or BB for 6 weeks.

Results

In the present study, several metabolic disorders were induced in our laboratory animal model, as evidenced by histological and biochemical changes. These alterations included serum and hepatic dyslipidemia (i.e., increased triglyceride, total cholesterol and low-density lipoprotein levels and decreased high-density lipoprotein levels), alterations in metabolic enzyme activities (lipase, glycerol-3-phosphate dehydrogenase, and glucose-6-phosphate dehydrogenase), histological changes in the liver (micro- and macrovesicular steatosis) and the downregulation of peroxisome proliferator-activated receptor γ (PPARγ) in adipose tissue and the liver. Daily oral supplementation with Q, CA or BB for 6 weeks after NAFLD induction had a hypolipidemic action and modulated metabolic markers.

Conclusion

We showed that an HFS diet is able to promote NAFLD, and our results suggest that CA and BB are promising complementary supplements that can ameliorate the metabolic disorders associated with an HFS diet; however, Q requires further investigation.

【 授权许可】

   
2015 Ragab et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Massiera F, Barbry P, Guesnet P, Joly A, Luquet S, Moreilhon-Brest C et al.. A Western-like fat diet is sufficient to induce a gradual enhancement in fat mass over generations. J Lipid Res. 2010; 51:2352-61.
• [2]Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol. 2011;2011:351982.
• [3]Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011; 7:456-65.
• [4]Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013; 152:673-84.
• [5]Chun M-R, Lee YJ, Kim K-H, Kim Y-W, Park S-Y, Lee K-M et al.. Differential effects of high-carbohydrate and high-fat diet composition on muscle insulin resistance in rats. J Korean Med Sci. 2010; 25:1053-9.
• [6]Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V et al.. High‐fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology. 2010; 52:934-44.
• [7]Murase T, Mizuno T, Omachi T, Onizawa K, Komine Y, Kondo H et al.. Dietary diacylglycerol suppresses high fat and high sucrose diet-induced body fat accumulation in C57BL/6 J mice. J Lipid Res. 2001; 42:372-8.
• [8]Sato A, Kawano H, Notsu T, Ohta M, Nakakuki M, Mizuguchi K et al.. Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet–induced obesity importance of hepatic lipogenesis. Diabetes. 2010; 59:2495-504.
• [9]Clarke SD. Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. J Nutr. 2001; 131:1129-32.
• [10]Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR et al.. Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003; 278:34268-76.
• [11]Vidal-Puig A, Jimenez-Liñan M, Lowell BB, Hamann A, Hu E, Spiegelman B et al.. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. Eur J Clin Invest. 1996; 97:2553.
• [12]Morán-Salvador E, López-Parra M, García-Alonso V, Titos E, Martínez-Clemente M, González-Périz A et al.. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte-and macrophage-specific conditional knockouts. FASEB J. 2011; 25:2538-50.
• [13]Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K et al.. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem. 2001; 276:41245-54.
• [14]Perez-Vizcaino F, Duarte J, Andriantsitohaina R. Endothelial function and cardiovascular disease: effects of quercetin and wine polyphenols. Free Radic Res. 2006; 40:1054-65.
• [15]Surh Y-J. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res. 1999; 428:305-27.
• [16]Park T, Kim Y. Phytochemicals as potential agents for prevention and treatment of obesity and metabolic diseases. Anti-Obes Drug Discov Dev Bentham, Dubai. 2011;1:150-185.
• [17]de Almeida ME, Mancini Filho J, Barbosa Guerra N. Characterization of antioxidant compounds in aqueous coriander extract Coriandrum sativum L.). LWT-Food Sci Technol. 2005; 38:15-9.
• [18]Yamamoto Y, Oue E. Antihypertensive effect of quercetin in rats fed with a high-fat high-sucrose diet. Biosci Biotechnol Biochem. 2006; 70:933-9.
• [19]Rivera L, Morón R, Sánchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity. 2008; 16:2081-7.
• [20]Stalikas CD. Extraction, separation, and detection methods for phenolic acids and flavonoids. J Sep Sci. 2007; 30:3268-95.
• [21]Crozier A, Jaganath IB, Clifford MN. Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep. 2009; 26:1001-43.
• [22]Luceri C, Guglielmi F, Lodovici M, Giannini L, Messerini L, Dolara P. Plant phenolic 4-coumaric acid protects against intestinal inflammation in rats. Scand J Gastroenterol. 2004; 39:1128-33.
• [23]Hsu C-L, Wu C-H, Huang S-L, Yen G-C. Phenolic compounds rutin and o-coumaric acid ameliorate obesity induced by high-fat diet in rats. J Agric Food Chem. 2009; 57:425-31.
• [24]Ziegler J, Facchini PJ. Alkaloid biosynthesis: metabolism and trafficking. Annu Rev Plant Biol. 2008; 59:735-69.
• [25]Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol-Endocrinol Metab. 2008; 294:E148-56.
• [26]Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee M-R et al.. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol-Endocrinol Metab. 2009; 296:E812-9.
• [27]McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983; 29:538-42.
• [28]Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20:470-5.
• [29]Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499-502.
• [30]Folch J, Lees M, Sloane-Stanley G. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957; 226:497-509.
• [31]Kozak LP, Jensen JT. Genetic and developmental control of multiple forms of L-glycerol 3-phosphate dehydrogenase. J Biol Chem. 1974; 249:7775-81.
• [32]Krieger N, Taipa M, Melo E, Lima-Filho J, Aires-Barros M, Cabral J. Purification of a Penicillium citrinum lipase by chromatographic processes. Bioprocess Eng. 1999; 20:59-65.
• [33]Mohany M, El-Feki M, Refaat I, Garraud O, Badr G: Thymoquinone ameliorates the immunological and histological changes induced by exposure to imidacloprid insecticide. J Toxicol Sci. 2012;37(1):1–11.
• [34]Angelova P, Boyadjiev N. A review on the models of obesity and metabolic syndrome in rats. Trakia J Sci. 2013; 11:5.
• [35]Raffaella C, Francesca B, Italia F, Marina P, Giovanna L, Susanna I. Alterations in hepatic mitochondrial compartment in a model of obesity and insulin resistance. Obesity. 2008; 16:958-64.
• [36]Cao L, Liu X, Cao H, Lv Q, Tong N. Modified high-sucrose diet-induced abdominally obese and normal-weight rats developed high plasma free Fatty Acid and insulin resistance. Oxid Med Cell Longev. 2012;2012:374346.
• [37]Conus F, Allison DB, Rabasa-Lhoret R, St-Onge M, St-Pierre DH, Tremblay-Lebeau A et al.. Metabolic and behavioral characteristics of metabolically obese but normal-weight women. J Clin Endocrin Metab. 2004; 89:5013-20.
• [38]Cho A-S, Jeon S-M, Kim M-J, Yeo J, Seo K-I, Choi M-S et al.. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol. 2010; 48:937-43.
• [39]Kanazawa M, Xue CY, Kageyama H, Suzuki E, Ito R, Namba Y et al.. Effects of a high‐sucrose diet on body weight, plasma triglycerides, and stress tolerance. Nutr Rev. 2003; 61:S27-33.
• [40]Teodoro JS, Duarte FV, Gomes AP, Varela AT, Peixoto FM, Rolo AP et al.. Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation. Mitochondrion. 2013; 13:637-46.
• [41]Abdelkarem HM, Fadda LH. Flaxseed and quercetin improves anti-inflammatory cytokines level and insulin sensitivity in animal model of metabolic syndrome fructose-fed rats. Afr J Pharm Pharmacol. 2013; 7:2452-8.
• [42]Jung UJ, Lee M-K, Park YB, Jeon S-M, Choi M-S. Antihyperglycemic and antioxidant properties of caffeic acid in db/db mice. J Pharmacol Exp Ther. 2006; 318:476-83.
• [43]Nagle CA, Klett EL, Coleman RA. Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res. 2009; 50:S74-9.
• [44]Yang Z-H, Miyahara H, Takeo J, Katayama M. Diet high in fat and sucrose induces rapid onset of obesity-related metabolic syndrome partly through rapid response of genes involved in lipogenesis, insulin signalling and inflammation in mice. Diabetol Metab Syndr. 2012; 4:32. BioMed Central Full Text
• [45]Henriksen BS, Curtis ME, Fillmore N, Cardon BR, Thomson DM, Hancock CR. The effects of chronic AMPK activation on hepatic triglyceride accumulation and glycerol 3-phosphate acyltransferase activity with high fat feeding. Diabetol Metab Syndr. 2013; 5:29. BioMed Central Full Text
• [46]Ramadan G, El-Beih NM, Abd El-Kareem HF. Anti-metabolic syndrome and immunostimulant activities of Egyptian fenugreek seeds in diabetic/obese and immunosuppressive rat models. Br J Nutr. 2011; 105:995-1004.
• [47]Sankhla M, Mathur K, Rathor JS. Is there any role of glucose-6-phosphate dehydrogenase in obesity induced metabolic disorder. Health. 2012; 4:1530.
• [48]Amin KA, Kamel HH, Eltawab MAA. Protective effect of Garcinia against renal oxidative stress and biomarkers induced by high fat and sucrose diet. Lipids Health Dis. 2011; 10:6. BioMed Central Full Text
• [49]BJaD SS. Familial lipoprotein lipase deficiency, Apo C–II deficiency, and hepatic lipase deficiency. The metabolic and molecular bases of inherited disease. 2001.2789-2816.
• [50]Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004; 89:2601-7.
• [51]Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Seminars in diagnostic pathology. 1998.246-258.
• [52]J-h F, Sun H-s, Wang Y, Zheng W-q, Shi Z-y, Wang Q-j. The effects of a fat-and sugar-enriched diet and chronic stress on nonalcoholic fatty liver disease in male Wistar rats. Dig Dis Sci. 2010; 55:2227-36.
• [53]Alisi A, Bruscalupi G, Pastore A, Petrini S, Panera N, Massimi M et al.. Redox homeostasis and posttranslational modifications/activity of phosphatase and tensin homolog in hepatocytes from rats with diet-induced hepatosteatosis. J Nutr Biochem. 2012; 23:169-78.
• [54]Xing L-J, Zhang L, Liu T, Hua Y-Q, Zheng P-Y, Ji G. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol. 2011; 668:467-71.
• [55]Ragab SMM, Omar HM, Sary K, Abd Elghaffar SK, El-Metwally TH. Hypolipidemic and antioxidant ef fects of phytochemical compounds against hepatic steatosis induced by high fat high sucrose diet in rats. Arch Biomed Sci. 2014; 2(1):1-10.
• [56]Lehrke M, Lazar MA. The many faces of PPARγ. Cell. 2005; 123:993-9.
• [57]Wei J, Bhattacharyya S, Varga J. Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol. 2010; 22:671-6.
• [58]Dong S-F, Hong Y, Liu M, Hao Y-Z, Yu H-S, Liu Y et al.. Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats. Eur J Pharmacol. 2011; 660:368-74.
• [59]Shih C-C, Lin C-H, Lin W-L. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract. 2008; 81:134-43.
• [60]Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol. 2008; 14(1):22-8.
• [61]Zhou J, Zhou S. Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. Eur J Pharmacol. 2010; 649:390-7.
• [62]Zhou X-R, Sun C-H, Liu J-R, Zhao D. Dietary conjugated linoleic acid increases PPARγ gene expression in adipose tissue of obese rat, and improves insulin resistance. Growth Horm IGF Res. 2008; 18:361-8.
• [63]Badr G. Camel whey protein enhances diabetic wound healing in a streptozotocin-induced diabetic mouse model: the critical role of β-Defensin-1,-2 and-3. Lipids Health Dis. 2013; 12(1):46. BioMed Central Full Text
• [64]Badr G. Supplementation with undenatured whey protein during diabetes mellitus improves the healing and closure of diabetic wounds through the rescue of functional long-lived wound macrophages. Cell Physiol Biochem. 2012; 29:571-82.
• [65]Al-Sadoon MK, Rabah DM, Badr G. Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: molecular targets for cell cycle arrest and apoptosis induction. Cell Immunol. 2013;284:129–38.
• [66]Badr G, Mohany M and Abou-Tarboush F. Thymoquinone decreases F-actin polymerization and proliferation of human multiple myeloma cells through suppression of STAT3 phosphorylation and Bcl2/Bcl-XL expression. Lipids Health Dis. 2011;10(1):236.
• [67]Badr G, Alwasel S, Ebaid H, Mohany M and Alhazza I. Perinatal Supplementation With Thymoquinone Improves Diabetic Complications and T Cell Immune Responses in Rat Offspring. Cell Immunol. 2011;267(2):133–40.
• [68]Badr G, Mohany M, Badr BM, Mahmoud MH, Rabah DM, Garraud O. Treatment of diabetic mice with undenatured whey protein enhances healing of diabetic wounds through the reduction of pro-inflammatory stimuli and modulation of the expression of MIP-1α, MIP-2, CX3CL1 and TGF-β. BMC Immunol. 2012;13(1):32.
• [69]Badr G, Ebaid H, Mohany M and Abu el-saad A: Modulation of immune cell proliferation and chemotaxis towards CC chemokine ligand (CCL)-21 and CXC chemokine ligand (CXCL)-12 in un-denatured whey protein-treated mice. J Nutr Biochem. 2012;23(12):1640–6.
• [70]Badr G, Garraud O, Daghestani M, Al-Khalifa M and Richard Y: Samsum Ant Venom Induces Apoptosis in MCF-7 Human Breast Carcinoma Cells and Inhibits IGF-1-mediaed Proliferation through PI3K/AKT and ERK Signaling Pathways. Cell Immunol. 2012;273(1):10–6.